TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05106556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy
Description: Programme will include diaphragmatic breathing exercise, pursed lip breathing exercise, thoracic expansion exercises, upper and lower extremity exercises, stretching the pectoral muscles, posture exercises, walking training and teaching respiratory control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Chest Physiotherapy
Description: Programme will include diaphragmatic breathing exercise, pursed lip breathing exercise, thoracic expansion exercises, upper and lower extremity exercises, stretching the pectoral muscles, posture exercises, walking training and teaching respiratory control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure with the threshold loading method.
Study: NCT03931330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous neurostimulation
Description: Percutaneous neurostimulation using NSS-2 Bridge device
Study: NCT03847584

Intervention type: OTHER
Intervention: Survey
Description: The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.

Intervention type: OTHER
Intervention: Survey
Description: The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.
Study: NCT05391893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral
Description: Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous drug
Description: these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
Study: NCT00334815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo thoracic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo thoracic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo thoracic radiotherapy
Study: NCT00785928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
Study: NCT00725374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tibolone
Description: one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
Study: NCT04497935

Intervention type: DRUG
Intervention: PLENVU
Description: Bowel preparation for a colonoscopy
Study: NCT03091062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monarch™ System
Description: Generates airflow at frequencies similar to those provided by HFCWO and also provides direct percussive therapy.
Study: NCT04440280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine (NAC) 20% solution
Description: N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Visine Dry Eye Relief eye drops
Description: Visine Tears Dry Eye Relief artificial tears ophthalmic solution
Study: NCT00656968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-day sequential treatment
Description: esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-day concomitant therapy
Description: esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
Study: NCT00908882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation Interviewing Counseling
Description: Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
Study: NCT04741152

Intervention type: PROCEDURE
Intervention: Pancreatic resection
Description: Different pancreatic resections

Intervention type: PROCEDURE
Intervention: Pancreatic resection
Description: Different pancreatic resections
Study: NCT00006102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Study: NCT00574067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine +OTP
Description: Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine +CHC
Description: Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Counseling +OTP
Description: Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Counseling +CHC
Description: Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
Study: NCT02497131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
Study: NCT06267794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone 1200 mg
Description: 1200 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone 1800 mg
Description: 1800 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
Study: NCT01677208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong injection
Description: A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study: NCT02291367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine Delayed-Release Capsules 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cymbalta®
Description: 60 mg capsule of Eli Lilly and Company
Study: NCT03842852

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Description: The grupo one underwent open repair and laparoscopic repair

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Description: The grupo one underwent open repair and laparoscopic repair
Study: NCT00330460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: ALN; 70 mg; oral; once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 60 mg; SC; every 6 months
Study: NCT00329628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
Study: NCT03540849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin (Bv)
Description: HL patients who are eligible for the study, will receive maintenance Bv. The first Bv dosage will be administered three months after allo-SCT (day 90) at the dosage of 1.8 mg/kg every 21 days for 12 cycles. post allo-SCT maintenance Bv for Hodgkin lymphoma
Study: NCT03677219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: The educational video is a 2 minute video depicting a live lumbar puncture on an infant interwoven with animations of the relevant anatomy.
Study: NCT03250455

Intervention type: DIAGNOSTIC_TEST
Intervention: CTA CTP
Description: CT Angiography myocardial CT Perfusion

Intervention type: DIAGNOSTIC_TEST
Intervention: CTA
Description: CT Angiography
Study: NCT02293460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I10E
Description: Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days.
Study: NCT01263886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombrabulin (AVE8062)
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT04649697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticulated Rebamipide
Description: A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer will be used in nanotechnology.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate
Description: A corticosteroid drug used as a gold standard for treatment of methotrexate induced oral ulceration.
Study: NCT01443689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: Participants will be given conventional therapy plus hUCMSCs transplantation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells
Description: Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
Study: NCT04497935

Intervention type: DRUG
Intervention: MoviPrep
Description: Bowel preparation for a colonoscopy
Study: NCT03089320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management Counseling
Description: Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addiction Physician Management
Description: Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol.
Study: NCT03847714

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omni-Biotic Stress Repair
Description: The probiotic supplement is a commercially available food for special medical purposes and includes 9 bacterial strains with at least 7.5 billion organisms (7.5 × 109 Colony Forming Units/g) per 1 portion (= 3 g).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: similar looking and tasting powder
Study: NCT02982668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial enteral feeding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial enteral feeding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial enteral feeding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide or mosapride
Description: gastrointestinal (GI) motility improving
Study: NCT03989700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine Mononitrate
Description: Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine Mononitrate
Description: Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine Mononitrate
Description: Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
Study: NCT02165657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser treatment
Description: Excimer laser irradiation twice a week for up to 20 treatments.
Study: NCT04348487

Intervention type: OTHER
Group type: OTHER
Intervention: Modified cephalica venous access
Description: This modified technique prioritized the safety in TIVAPS by using several modified landmarks and techniques. The catheter was inserted through cephalic vein in deltopectoral groove regio and implanted the port in the anteromedial of thorax. Generally, the percutaneous and Seldinger technique was used to ensure safety and minimal tissue disruption. To connect the trimmed catheter to port pocket, the author anchored a special trocar from anteromedial of thorax to the deltopectoral groove for guidance.
Study: NCT03397277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety behaviour promoting video
Description: A 7 min. video which teaches 15 different safety behaviours to reduce violence or the effect of violence

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control video
Description: A 7 min. video which teaches women about safety regarding food, alcohol, smoking, medication and physical activity during pregnancy
Study: NCT03140930

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tastants duodenal
Description: Duodenal infusion of combination of tastants (sweet, bitter and umami)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tastants duodenal
Description: Duodenal infusion of combination of tastants (sweet, bitter and umami)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tastants ileal
Description: Ileal infusion of combination of tastants (sweet, bitter and umami)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tastants ileal
Description: Ileal infusion of combination of tastants (sweet, bitter and umami)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo duodenal
Description: Duodenal infusion of placebo (tap water)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo duodenal
Description: Duodenal infusion of placebo (tap water)
Study: NCT03476993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-085
Description: All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.
Study: NCT04047329

Intervention type: OTHER
Intervention: general anesthesia or neuraxial anesthesia
Study: NCT03140930

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ileal
Description: Ileal infusion of placebo (tap water)
Study: NCT03667196

Intervention type: PROCEDURE
Intervention: antegrade and retrograde approach
Description: This study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO
Study: NCT03140930

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo ileal
Description: Ileal infusion of placebo (tap water)
Study: NCT00952289

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib phosphate tablets 5 mg administered as oral doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib phosphate tablets 5 mg administered as oral doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets were administered as oral doses in the same manner as active drug.